Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib Schedule 4/2 vs 2/1 in mRCC
NCT02398552Phase 2Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Mar 2015
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sunitinib in metastatic renal cell carcinoma (mRCC), sponsored by Peking University Cancer Hospital & Institute. Status: unknown.
02
Drugs
sunitinib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT02398552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02398552.